CA
NZ
UK
AU
IND
US
Brian T. Hamilton, a director and President of CCBX at Coastal Financial Corp, filed a Form 4 on September 1, 2026, reporting the disposition of 232 shares of common stock through a tax withholding transaction tied to a Rule 10b5-1 trading plan.
A statement of changes in beneficial ownership was filed on September 1, 2026, disclosing that Marillyn A. Hewson, a director of Chevron Corp (NYSE:CVX), acquired 213 shares of phantom stock on August 28, 2026, under the company's Non-Employee Directors' Equity Compensation and Deferral Plan.
Dyal Capital SLP LP filed a Form 4 with the SEC on September 1, 2026, disclosing the disposition of 500,000 Class D shares of Blue Owl Capital Inc. (NYSE:OWL) and an equal number of Blue Owl Operating Group Units for no consideration.
Cynthia J. Warner, a director of Chevron Corp, filed a Form 4 on September 1, 2026, disclosing a phantom stock transaction dated August 28, 2026, under the Chevron Non-Employee Directors' Equity Compensation and Deferral Plan.
A Form 4 filed with the SEC on September 1, 2026 discloses that Ichi Shih, a director of WhiteFiber, Inc. (NASDAQ:WYFI), sold 7,059 ordinary shares on May 29, 2026 at a price of $30.12 per share.
A Form 4 filed with the SEC on September 1, 2026, reports that Elisa Steele, a director of JFrog Ltd. (NASDAQ:FROG), disposed of 554 ordinary shares on August 28, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Director Diana J. Walters filed a Form 4 with the SEC on September 1, 2026, disclosing the acquisition of Deferred Share Units in Trilogy Metals Inc., listed on NYSE:TMQ.
Director Anthony Mathew Eisen of Block, Inc. filed a Form 4 on September 1, 2026, reporting the sale of 18,000 shares of Class A Common Stock across three transactions between August 28 and September 1, 2026.
A Form 4 filed on September 1, 2026 reports that Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on September 1, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., filed a Form 4 on September 1, 2026, reporting the sale of 16,666 shares of common stock executed pursuant to a pre-established Rule 10b5-1 trading plan.
Please wait processing your request...